Eli Lilly expanded its drug discovery alliance with Gate Bioscience in a potential US$870m multi-year deal. The broadened collaboration targets difficult-to-drug proteins using Gate Bioscience's discovery platform across high unmet-need disease areas. Under the expanded agreement, Lilly obtained global development and commercialization rights for therapies emerging from the partnership. The deal deepens Lilly's push into hard-to-drug biology and adds another external engine alongside partners such as InnoCare and tools accessed through TuneLab, though whether these molecular gate programs can advance quickly into late-stage assets remains an open question.
Eli Lilly and CompanyLilly expanded its drug discovery alliance with Gate Bioscience, gaining global rights to therapies targeting difficult-to-drug proteins via Gate's discovery platform.
InnoCare Pharma Ltd. A